Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2016 · 10-Q
Revenue$3.04M$3.04M−92.1% vs Q1 2015 Net Income-$5.30M-$5.30MN/M vs Q1 2015 EPS Diluted-$2.69-$2.69N/M vs Q1 2015 Gross Profit$1,856,000+241.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$3,970,000N/M Margins · derivedGross margin61.2%+59.7 pt vs Q1 2015
Operating margin-125.2%−109.2 pt vs Q1 2015
Net margin-174.5%−162.5 pt vs Q1 2015
ended Mar 31, 2016 · filed May 12, 2016 · 42 d after period end